All updated as on -
Starting at USD 2.10 Billion in 2022, the Spine Biologics Market is expected to reach USD 4.7 Billion by 2030, expanding at a CAGR (Compound Annual Growth Rate) of 5.90% between 2023 and 2030. The increasing prevalence of spine disorders and the ageing population are the primary growth factors for this industry.
The term "biologic material" is used to describe a substance that contributes to the progression of a biological process that modifies its surrounding environment. Cellular activity, differentiation, and growth all improve as a result. Bone fusion, degenerative disc disease, and spinal cord injuries all make substantial use of the materials that make up spine biologics.
The primary reasons driving the growth of the spine biologics market are the worldwide increase in the prevalence of degenerative spine illnesses and the considerable increase in the prevalence of treatment. The rising need for minimally invasive spine surgeries, the increasing sophistication of bone grafting techniques, and the overall importance of these biologics all contribute to the expansion of the spine biologics market. The rapid healing, short postoperative time, and the potential to trigger cellular expansion offered by biomaterials for the treatment of degenerative disc disease, spinal cord injuries, and bone fusion procedures all contribute to the growth of the spine biologics market. The market for spine biologics is also bolstered by factors such as an ageing population, rising healthcare spending, more research and development, and greater public knowledge of innovative spine treatment methods. An ageing population, a rise in spinal deformities, and breakthroughs in bone grafting technology are propelling the global industry. The increased prevalence of degenerative spine diseases and the rising popularity of less invasive procedures are also fueling market growth. In addition, the two most common cutting-edge biological approaches employed by surgeons around the world to treat spinal abnormalities are interbody fusion and direct lateral interbody fusion.
Lateral body fusion is the ideal way for treating spinal illnesses since it results in fewer complications and allows for a speedy and safe recovery, thanks to the utilisation of recent breakthroughs in biomaterials. It increases the need for spine biologics in the treatment of disc degeneration, sclerosis, and other spine-related diseases. With a growing senior population comes a higher need for medical care and diagnostics. People over the age of 50 have a higher risk of spinal injuries due to structural changes in the spine or spinal abnormalities. These factors, among others, are expected to propel the spine biologics market over the forecast period. The increasing prevalence of degenerative spine illnesses and the dramatic uptick in global treatment rates are the key factors driving the expansion of the spine biologics market.
Spine biologics devices are utilised in spine surgery as substitutes for allografts and to provide structural support for vertebrae and other vertebral body bones. When compared to traditional spinal fusion methods using pedicle rods and screws, these implants have many advantages. Metals are inert, therefore they don't do anything to the cells themselves, thus they can't promote or trigger cellular growth or affect cellular activities like natural healing. However, spine biologics stimulate spine fusion, which in turn activates cellular proliferation. The increasing prevalence of spinal disorders, rising healthcare spending in developing countries as a result of rising income levels, the prevalence of obesity, growing awareness of newly developed spine treatment techniques and devices, technological advances, and the increasing demand for minimally invasive spine surgeries are all factors that are propelling the global spinal biologics market. The high cost of surgery and an unfavourable reimbursement condition are two of the key factors holding this market back.
Allografts have long been regarded as the best option for bone regeneration in the spine. Allograft bones used to be the standard, but they have since been replaced by biological alternatives including bone morphogenetic proteins (BMP), demineralized bone matrix (DBM), and bone substitutes due to issues like donor site difficulties, high surgical expense, extensive surgical procedures, and prolonged recovery time. Bone morphogenetic proteins (BMPs) encourage bone formation and spinal fusion. They eliminate the need for bone harvesting from the patient, which means less discomfort after surgery, shorter hospital stays, and a quicker recovery. Clinical trials aimed at expanding its use in the surgical treatment of degenerative disc disease in the spine are now underway.
There has been a worldwide increase in the prevalence of spinal conditions. The global spine biologics market grows rapidly because people over the age of 60 are at a higher risk of developing spine disorders and having surgical fusions performed as a treatment. Despite its controversial status in terms of research, evidence, and potential problems, it has become a standard feature of many spinal operations. For surgeons to take into account biological healing of the actual fusion, bone transplants are an essential advantage. One in ten adults experiences lower back pain (LBP), per research published in the Annals of Rheumatic Diseases. The World Health Organisation (WHO) reported in 2013 that between 250,000 and 300,000 people are living with spinal cord injury. The leading causes of injury include traffic incidents, acts of aggression, and accidental falls. According to the National Spinal Cord Injury Statistical Centre (NSCISC), around 285,000 people in the United States sustained some form of spinal cord injury in 2017. Key players face difficulties due to the government's stringent rules and regulations in authorising new items and their debut in regards to people's safety. Because of their human source, allografts are osteoconductive and osteoinductive but lack osteogenic properties because they are devoid of living cells. There is also a small chance of contracting hepatitis B or hepatitis C during the radiation sterilisation process, and unfavourable changes in bone matrix composition are another constraint. Market expansion is also slightly hampered by our incomplete understanding of spine biologics and treatment methods.
Report Coverage
Global Spine Biologics research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Spine Biologics report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Spine Biologics competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Spine Biologics market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Spine Biologics market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Spine Biologics market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Arthrex, Inc., Cesca Therapeutics Inc., DePuy Synthes, Orthopaedic Seminar, Exactech, Inc., K2M, Inc., Lattice Biologics Ltd, Medtronic, NuTech Spine, Inc., NuVasive Inc., Orthofix Holdings, Inc., Regen Lab USA LLC, RTI Surgical Holdings, Inc., Stryker, Wright Medical Group N.V., XTANT MEDICAL, Zimmer Biomet, Smith & Nephew, Dr PRP USA LLC
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Spine Biologics market based on the below-mentioned segments:
Global Spine Biologics Market, By Product
Bone Allografts
Bone Graft Substitute
Platelet Rich Plasma
Bone Marrow Aspirate Therapy
Global Spine Biologics market, By Surgery Type
Anterior Cervical Discectomy and Fusion (ACDF)
Transforamenal Lumbar Interbody Fusion (TLIF)
Anterior Lumbar Interbody Fusion (ALIF)
Lateral Lumbar Interbody Fusion (LLIF)
Global Spine Biologics Market, By End User
Hospitals
Spinal Surgery Centers
Orthopedic Clinics,
Others
Global Spine Biologics market, Regional Analysis
The term "biologic material" is used to describe a substance that contributes to the progression of a biological process that modifies its surrounding environment. Cellular activity, differentiation, and growth all improve as a result. Bone fusion, degenerative disc disease, and spinal cord injuries all make substantial use of the materials that make up spine biologics.
The primary reasons driving the growth of the spine biologics market are the worldwide increase in the prevalence of degenerative spine illnesses and the considerable increase in the prevalence of treatment. The rising need for minimally invasive spine surgeries, the increasing sophistication of bone grafting techniques, and the overall importance of these biologics all contribute to the expansion of the spine biologics market. The rapid healing, short postoperative time, and the potential to trigger cellular expansion offered by biomaterials for the treatment of degenerative disc disease, spinal cord injuries, and bone fusion procedures all contribute to the growth of the spine biologics market. The market for spine biologics is also bolstered by factors such as an ageing population, rising healthcare spending, more research and development, and greater public knowledge of innovative spine treatment methods. An ageing population, a rise in spinal deformities, and breakthroughs in bone grafting technology are propelling the global industry. The increased prevalence of degenerative spine diseases and the rising popularity of less invasive procedures are also fueling market growth. In addition, the two most common cutting-edge biological approaches employed by surgeons around the world to treat spinal abnormalities are interbody fusion and direct lateral interbody fusion.
Lateral body fusion is the ideal way for treating spinal illnesses since it results in fewer complications and allows for a speedy and safe recovery, thanks to the utilisation of recent breakthroughs in biomaterials. It increases the need for spine biologics in the treatment of disc degeneration, sclerosis, and other spine-related diseases. With a growing senior population comes a higher need for medical care and diagnostics. People over the age of 50 have a higher risk of spinal injuries due to structural changes in the spine or spinal abnormalities. These factors, among others, are expected to propel the spine biologics market over the forecast period. The increasing prevalence of degenerative spine illnesses and the dramatic uptick in global treatment rates are the key factors driving the expansion of the spine biologics market.
Spine biologics devices are utilised in spine surgery as substitutes for allografts and to provide structural support for vertebrae and other vertebral body bones. When compared to traditional spinal fusion methods using pedicle rods and screws, these implants have many advantages. Metals are inert, therefore they don't do anything to the cells themselves, thus they can't promote or trigger cellular growth or affect cellular activities like natural healing. However, spine biologics stimulate spine fusion, which in turn activates cellular proliferation. The increasing prevalence of spinal disorders, rising healthcare spending in developing countries as a result of rising income levels, the prevalence of obesity, growing awareness of newly developed spine treatment techniques and devices, technological advances, and the increasing demand for minimally invasive spine surgeries are all factors that are propelling the global spinal biologics market. The high cost of surgery and an unfavourable reimbursement condition are two of the key factors holding this market back.
Allografts have long been regarded as the best option for bone regeneration in the spine. Allograft bones used to be the standard, but they have since been replaced by biological alternatives including bone morphogenetic proteins (BMP), demineralized bone matrix (DBM), and bone substitutes due to issues like donor site difficulties, high surgical expense, extensive surgical procedures, and prolonged recovery time. Bone morphogenetic proteins (BMPs) encourage bone formation and spinal fusion. They eliminate the need for bone harvesting from the patient, which means less discomfort after surgery, shorter hospital stays, and a quicker recovery. Clinical trials aimed at expanding its use in the surgical treatment of degenerative disc disease in the spine are now underway.
There has been a worldwide increase in the prevalence of spinal conditions. The global spine biologics market grows rapidly because people over the age of 60 are at a higher risk of developing spine disorders and having surgical fusions performed as a treatment. Despite its controversial status in terms of research, evidence, and potential problems, it has become a standard feature of many spinal operations. For surgeons to take into account biological healing of the actual fusion, bone transplants are an essential advantage. One in ten adults experiences lower back pain (LBP), per research published in the Annals of Rheumatic Diseases. The World Health Organisation (WHO) reported in 2013 that between 250,000 and 300,000 people are living with spinal cord injury. The leading causes of injury include traffic incidents, acts of aggression, and accidental falls. According to the National Spinal Cord Injury Statistical Centre (NSCISC), around 285,000 people in the United States sustained some form of spinal cord injury in 2017. Key players face difficulties due to the government's stringent rules and regulations in authorising new items and their debut in regards to people's safety. Because of their human source, allografts are osteoconductive and osteoinductive but lack osteogenic properties because they are devoid of living cells. There is also a small chance of contracting hepatitis B or hepatitis C during the radiation sterilisation process, and unfavourable changes in bone matrix composition are another constraint. Market expansion is also slightly hampered by our incomplete understanding of spine biologics and treatment methods.
Report Coverage
Global Spine Biologics research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Spine Biologics report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Spine Biologics competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Spine Biologics market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Arthrex, Inc., Cesca Therapeutics Inc., DePuy Synthes, Orthopaedic Seminar, Exactech, Inc., K2M, Inc., Lattice Biologics Ltd, Medtronic, NuTech Spine, Inc., NuVasive Inc., Orthofix Holdings, Inc., Regen Lab USA LLC, RTI Surgical Holdings, Inc., Stryker, Wright Medical Group N.V., XTANT MEDICAL, Zimmer Biomet, Smith & Nephew, Dr PRP USA LLC |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Spine Biologics Market from 2021 to 2030.
- Market Forecast for Spine Biologics Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Spine Biologics competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Spine Biologics
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Spine Biologics market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Spine Biologics market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Arthrex, Inc., Cesca Therapeutics Inc., DePuy Synthes, Orthopaedic Seminar, Exactech, Inc., K2M, Inc., Lattice Biologics Ltd, Medtronic, NuTech Spine, Inc., NuVasive Inc., Orthofix Holdings, Inc., Regen Lab USA LLC, RTI Surgical Holdings, Inc., Stryker, Wright Medical Group N.V., XTANT MEDICAL, Zimmer Biomet, Smith & Nephew, Dr PRP USA LLC
Primary Target Market
- Market Players of Spine Biologics
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Spine Biologics market based on the below-mentioned segments:
Global Spine Biologics Market, By Product
Bone Allografts
Bone Graft Substitute
Platelet Rich Plasma
Bone Marrow Aspirate Therapy
Global Spine Biologics market, By Surgery Type
Anterior Cervical Discectomy and Fusion (ACDF)
Transforamenal Lumbar Interbody Fusion (TLIF)
Anterior Lumbar Interbody Fusion (ALIF)
Lateral Lumbar Interbody Fusion (LLIF)
Global Spine Biologics Market, By End User
Hospitals
Spinal Surgery Centers
Orthopedic Clinics,
Others
Global Spine Biologics market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive spine biologics market market research and competitor analysis for your business to help you develop more profound insights into the spine biologics market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the spine biologics market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.